Skip to main content
OpenTrials
Completed

NCT Number: NCT01382329

H5N1 Vaccine Study in Japanese Adults

The purpose of this study is to obtain immunogenicity and safety data of two different dose levels of an H5N1 pandemic influenza vaccine in a healthy Japanese adult population aged 18 to 59 years.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–59 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Medical Co. LTA PS Clinic, Fukuoka, Japan

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is 18 to 59 years old at the time of screening
  • Subject is generally healthy, as determined by the investigator´s clinical judgement through collection of medical history and performance of a physical examination
  • Subject is physically and mentally capable of participating in the study and willing to adhere to study procedures to include completion of all elements of the study diary
  • If female of childbearing potential, subject presents with a negative urine pregnancy test result within 24 hours prior ot the scheduled first vaccination and agrees to employ adequate birth control measures for the duration of the study

Exclusion criteria

  • Subject has a history of infectin with H5N1 virus or a history of vaccination with an H5N1 influenza vaccine
  • Subject is at high risk of contracting H5N1 influenza infection (e.g. poultry workers)
  • Subject currently has or has a history of a significant cardiovascular (including hypertension), respiratory (including asthma), metabolic, neurological (including Guillain-Barré Syndrome and acute disseminated encephalomyelitis), hepatic, rheumatic, autoimmune, hematological, gastrointestinal or renal disorder
  • Subject has any inherited or acquired immunodeficiency
  • Subject has a disease or is currently undergoing a form of treatment or was undergoing a form of treatment within 30 days prior to study entry that can be expected to influence immune response. Such treatment includes, but is not limited to: systemic or inhaled corticosteroids, radiation treatment, or other immunosuppressive or cytotoxic drugs
  • Subject has a history of severe allergic reactions or anaphylaxis
  • Subject has a rash, dermatologic condition or tattoos which may interfere with injection site reaction rating
  • Subject has received a blood transfusion or immunoglobulins within 90 days prior to study entry
  • Subject has donated blood or plasma within 30 days prior to study entry
  • Subject has received any influenza or any live vaccine within 4 weeks or any other inactivated vaccine within 2 weeks prior to vaccination in this study
  • Subject has a functional or surgical asplenia
  • Subject has a known or suspected problem with alcohol or drug abuse
  • Subject was administered an investigational drug within 6 weeks prior to study entry or is concurrently participating in a clinical study that includes the administration of an investigational product
  • Subject is a member of the team conducting this study or is in a dependent relationship with one of the study team members. Dependent relationships include close relatives (i.e., children, partner/spouse, siblings, parents) as well as employees of the investigator/subinvestigator or site personnel conducting the study
  • If female, subject is pregnant or lactating at the time of enrollment
  • Subject has any other condition that disqualifies his/her participation in the study in the opinion of the investigator

Treatment and study plan

H5N1 (pre-)pandemic influenza vaccine (whole virion, Vero Cell derived, inactivated)

Biological

Intramuscular injection into the musculus deltoideus or subcutaneous injection in the upper arm

Primary outcomes

  1. Number of subjects with antibody response to the vaccine strain

    Time frame: 21 days after 2nd vaccination

    Measurement by single radial hemolysis (SRH) assay

  2. Number of subjects demonstrating seroconversion

    Time frame: 21 days after 2nd vaccination

    Measurement by SRH assay

  3. Fold increase of antibody response

    Time frame: 21 days after 2nd vaccination

    Measurement by SRH assay

Secondary outcomes

  1. Number of subjects with antibody response to the vaccine strain

    Time frame: 21 days after 1st and 21+180 days after 2nd vaccination

    Measurement by SRH (except at 21 days after 2nd vaccination), microneutralization (MN) and hemagglutination inhibition (HI) assay

  2. Number of subjects demonstrating seroconversion

    Time frame: 21 days after 1st and 21+180 days after 2nd vaccination

    Measurement by SRH (except at 21 days after 2nd vaccination), MN and HI assay

  3. Antibody response

    Time frame: 21 days after 1st and 21 + 180 days after 2nd vaccination

    Measurement by SRH, MN and HI assay

  4. Fold increase of antibody response

    Time frame: 21 days after 1st and 21+180 days after 2nd vaccination as compared to baseline

    Measurement by SRH (except at 21 days after 2nd vaccination), MN and HI assay

Sponsors and collaborators

Lead sponsor

Alachua Government Services, Inc.

Industry

Collaborators

  • Baxter Innovations GmbH

Registry information

Official study title

A Blinded, Randomized Phase 2/3 Study to Assess Immunogenicity and Safety of Two Different Dose Levels of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Healthy Japanese Adult Population Aged 18 to 59 Years

Important dates

Study start
2011
Primary completion
2011
Study completion
2012
First posted
Jun 27, 2011
Registry last updated
Oct 9, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.